hydroxyurea has been researched along with HIV Coinfection in 149 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination." | 9.11 | Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. ( Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005) |
| "A 1993 presentation described the role of hydroxyurea in inhibiting HIV replication in peripheral blood mononuclear cells and macrophages as well as a synergistic effect with ddI." | 9.08 | Hydroxyurea in HIV therapy. ( , 1998) |
| "A new notice was distributed to health care providers cautioning of the increased risk of fatal and nonfatal pancreatitis for patients taking didanosine (Videx) from Bristol-Meyers Squibb." | 7.70 | Extended warning on Didanosine-related pancreatitis. ( , 1999) |
| " and Europe supports the effect of the anticancer drug hydroxyurea against HIV-1, and its potential synergistic effect with ddl." | 7.69 | Hydroxyurea, a potential new anti-HIV agent. ( Torres, G, 1995) |
| "Hydroxyurea was not found to be beneficial when used in association with STIs in patients during PHI." | 6.72 | The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). ( Bloch, MT; Carr, A; Cooper, DA; Finlayson, RJ; Grey, P; Irvine, K; Kaldor, JM; Kelleher, AD; Law, M; McFarlane, R; Petoumenos, K; Quan, D; Smith, DE; Zaunders, JJ, 2006) |
| "The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination." | 5.11 | Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. ( Asmuth, D; Bakare, N; Blick, G; Farthing, C; Foli, A; Frank, I; Greiger, P; Groff, A; Herman, D; Lisziewicz, J; Lori, F; Lova, L; Norris, D; Peterson, D; Pollard, RB; Rashbaum, B; Schrader, S; Shalit, P; Tennenberg, A; Whitman, L, 2005) |
| "A 1993 presentation described the role of hydroxyurea in inhibiting HIV replication in peripheral blood mononuclear cells and macrophages as well as a synergistic effect with ddI." | 5.08 | Hydroxyurea in HIV therapy. ( , 1998) |
| " Incidence rates of pancreatitis were calculated for each antiretroviral regimen that included zidovudine, stavudine, didanosine (+ hydroxyurea), and didanosine + stavudine (+ hydroxyurea)." | 3.71 | Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. ( Chaisson, RE; Keruly, JC; Moore, RD, 2001) |
| "A new notice was distributed to health care providers cautioning of the increased risk of fatal and nonfatal pancreatitis for patients taking didanosine (Videx) from Bristol-Meyers Squibb." | 3.70 | Extended warning on Didanosine-related pancreatitis. ( , 1999) |
| "Hydroxyurea obstructs HIV from reproducing, is effective when combined with nucleoside analogue reverse transcriptase inhibitors, and it is difficult for HIV to develop a resistance to it." | 3.70 | Hydroxyurea - new observations. ( , 1998) |
| " and Europe supports the effect of the anticancer drug hydroxyurea against HIV-1, and its potential synergistic effect with ddl." | 3.69 | Hydroxyurea, a potential new anti-HIV agent. ( Torres, G, 1995) |
| "Hydroxyurea was not found to be beneficial when used in association with STIs in patients during PHI." | 2.72 | The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse). ( Bloch, MT; Carr, A; Cooper, DA; Finlayson, RJ; Grey, P; Irvine, K; Kaldor, JM; Kelleher, AD; Law, M; McFarlane, R; Petoumenos, K; Quan, D; Smith, DE; Zaunders, JJ, 2006) |
| "The safety and efficacy of hydroxyurea with didanosine in combination with stavudine in nucleoside reverse-transcriptase inhibitor (NRTI)-experienced patients was investigated." | 2.71 | Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature. ( Andron, L; Asmuth, DM; Grady, JJ; Green, S; McKinsey, DS; Pollard, RB; Rossero, R, 2003) |
| "Hydroxyurea (HU) has preferential activity in virus reservoirs not effectively targeted by current antiretroviral drug regimens, but concern for potential toxicity has precluded its routine use." | 2.71 | Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression. ( Bosch, RJ; Collier, A; Malhotra, U; McElrath, MJ; Wang, R, 2004) |
| "Hydroxyurea (HU) is an immunomodulatory agent that has been documented to enhance the antiretroviral activity of nucleoside reverse transcriptase inhibitors, such as abacavir (ABC) and didanosine (ddI), and would be expected to improve virologic efficacy." | 2.71 | Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. ( Berger, DS; Cohen, CJ; Hernandez, JE; Liao, Q; Pakes, GE; Pobiner, BF; Snidow, JW; Swindells, S; Tashima, KT, 2005) |
| "Hydroxyurea has been administered with nucleoside analogues to modulate intracellular dNTP pools and thus the ratio of drug triphosphate:endogenous triphosphate." | 2.70 | Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. ( Almond, LM; Back, DJ; De Vries, C; Gould, J; Hoggard, PG; Kewn, S; Khoo, SH; Lou, Y; Maherbe, A; Sales, SD; Wood, R, 2002) |
| " Overall, in 12 patients treated with hydroxyurea, 33 adverse events were reported versus 19 reported for 12 patients who did not receive hydroxyurea (p <." | 2.70 | Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. ( Cahn, P; Federico, A; Kijak, G; Montaner, JS; Ochoa, C; Perez, H; Salomon, H; Zala, C, 2002) |
| " Hydroxyurea's dosage level is still uncertain; 500 mg twice daily has been used most often." | 2.69 | Hydroxyurea for HIV infection. ( Davis, B; Zachary, KC, 1998) |
| "Hydroxyurea was found to induce lymphopenia (-124 x 10(6)/l)." | 2.69 | A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. ( Bernasconi, E; Bucher, HC; Hirschel, B; Iten, A; Leduc, D; Malinverni, R; Opravil, M; Perrin, LH; Rutschmann, OT; Sudre, P; Vernazza, PL; Yerly, S, 1998) |
| " Nine patients receiving hydroxyurea in monotherapy (n = 4) or in combination with AZT (n = 5) agreed to undergo multiple venipunctures for pharmacokinetic analysis." | 2.68 | Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I. ( Giacchino, R; Lori, F; Maserati, R; Regazzi, MB; Villani, P, 1996) |
| " Since hydroxyurea-related toxicity is dose dependent, a systematic study of hydroxyurea optimal dosage and schedule was initiated to monitor patients for possible nucleoside toxicity." | 2.42 | Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns. ( Foli, A; Lisziewicz, J; Lori, F; Wainberg, M, 2003) |
| "Factors affecting patient adherence to therapy, such as frequent daily dosing and complex dosing schedules, are widely understood to be key obstacles to the durability of effective anti-HIV therapy." | 2.41 | Didanosine once daily: potential for expanded use. ( Pollard, RB, 2000) |
| "Hydroxyurea was also found to be synergistic with the nucleoside reverse transcriptase inhibitor didanosine and to inhibit HIV-1 replication in activated PBMC; this inhibition may be due to a reduction in deoxynucleoside triphosphate pool sizes." | 2.41 | Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. ( Lisziewicz, J; Lori, F, 2000) |
| " The adjunctive antiviral effect of hydroxyurea-as well as its favorable dosing schedule, safety profile, and cost-makes it a very attractive addition to our therapeutic armamentarium." | 2.41 | Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection. ( Montaner, JS; Rouleau, D; Zala, C, 2000) |
| "Hydroxyurea is an anticancerous product, used recently in the treatment of HIV-1 infection thanks to its inhibitory action in viral replication, potentialization of the nucleosides activity (particularly ddI or didanosine) and its cytostatic properties on CD4 and CD8 lymphocytes." | 2.41 | [Hydroxyurea and HIV infection]. ( Demonty, J; Kola, L; Léonard, P; Moutschen, M; Nkoghe, D, 2000) |
| "Thalidomide has shown potential in treating some AIDS-related conditions [cachexia (weight loss and muscle wasting), and aphtous oral, oesophageal or genital ulcers]." | 2.40 | New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide. ( Lisziewicz, J; Lori, F; Ravot, E, 1999) |
| "Hydroxyurea is a ribonucleotide reductase inhibitor that may have efficacy against HIV." | 2.40 | Hydroxyurea to inhibit human immunodeficiency virus-1 replication. ( Pomeroy, C; Romanelli, F; Smith, KM, 1999) |
| " Additional studies will determine the optimum dosage and schedule for hydroxyurea and its effects when used with other agents and in patients with advanced disease or extensive pretreatment." | 2.40 | Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects. ( Lisziewicz, J; Lori, F, 1999) |
| " Cerebrospinal fluid (CSF) and plasma drug concentrations were measured over 8 hours and simultaneously fitted to a pharmacokinetic model." | 1.32 | Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients. ( Gwilt, PR; Manouilov, KK; McNabb, J; Swindells, SS, 2003) |
| " Hydroxyurea was held temporarily during the first month of therapy in 4 cases because of neutropenia; all patients resumed hydroxyurea at full dosage without recurrence of neutropenia." | 1.31 | Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine. ( Calles, NR; Kline, MW; Schwarzwald, H; Simon, C, 2000) |
| " Combining d4T/ddI with protease inhibitors presents problems, such as a complicated dosing schedule and harsh gastrointestinal side effects." | 1.30 | Dethroning AZT. ( Falkenberg, J; Gilden, D; Torres, G, 1997) |
| " Study results of twice-daily dosing regimens of indinavir and nelfinavir look promising." | 1.30 | Drug research shows easier dosing, new combinations are making gains. ( , 1998) |
| " Hydroxyurea's side effects, dosage requirements, and method of reducing HIV in the body are discussed." | 1.30 | Hydroxyurea for HIV? ( , 1998) |
| "Hydroxyurea has been shown to potentiate the anti-human immunodeficiency virus activities of 2',3'-dideoxynucleoside analogs such as didanosine." | 1.30 | Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs. ( De Clercq, E; Neyts, J, 1999) |
| " Areas examined included resistance to new antiretroviral agents, the use of Hydroxyurea as a standard therapy, novel dosing strategies, new antiretroviral agents, and dual protease inhibitor therapy." | 1.30 | Antiretroviral news. ( Gallant, JE, 1998) |
| " As a potent alternative to HAART, NNRTI's offer easier dosing and appear to have similar results, albeit in the short-term." | 1.30 | Antivirals update. ( , 1998) |
| "Hydroxyurea (Hydrea) is an antiviral drug approved for use against cancer and sickle cell anemia." | 1.30 | Hydroxyurea: what it is. New Mexico AIDS InfoNet. ( , 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 77 (51.68) | 18.2507 |
| 2000's | 67 (44.97) | 29.6817 |
| 2010's | 5 (3.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rawson, JM | 1 |
| Roth, ME | 1 |
| Xie, J | 1 |
| Daly, MB | 1 |
| Clouser, CL | 1 |
| Landman, SR | 1 |
| Reilly, CS | 1 |
| Bonnac, L | 1 |
| Kim, B | 1 |
| Patterson, SE | 1 |
| Mansky, LM | 1 |
| Fraser, DI | 1 |
| Liu, KT | 1 |
| Reid, BJ | 1 |
| Hawkins, E | 1 |
| Sevier, A | 1 |
| Pyle, M | 1 |
| Robinson, JW | 1 |
| Ouellette, PH | 1 |
| Ballantyne, JS | 1 |
| Stein, J | 1 |
| Storcksdieck Genannt Bonsmann, M | 1 |
| Streeck, H | 1 |
| Kovacic, P | 1 |
| Uglietti, A | 1 |
| Maserati, R | 5 |
| Gonzalez, OY | 1 |
| Jovanovich, JF | 1 |
| Mayers, DL | 1 |
| Musher, DM | 1 |
| Shirlaw, PJ | 1 |
| Chikte, U | 1 |
| MacPhail, L | 1 |
| Schmidt-Westhausen, A | 1 |
| Croser, D | 1 |
| Reichart, P | 1 |
| Flexner, C | 3 |
| Bartlett, JG | 1 |
| Hoggard, PG | 1 |
| Kewn, S | 1 |
| Maherbe, A | 1 |
| Wood, R | 2 |
| Almond, LM | 1 |
| Sales, SD | 1 |
| Gould, J | 1 |
| Lou, Y | 1 |
| De Vries, C | 1 |
| Back, DJ | 1 |
| Khoo, SH | 1 |
| García, F | 2 |
| Plana, M | 1 |
| Arnedo, M | 1 |
| Ortiz, GM | 1 |
| Miró, JM | 1 |
| Lopalco, L | 1 |
| Lori, F | 21 |
| Pumarola, T | 1 |
| Gallart, T | 1 |
| Gatell, JM | 2 |
| Rossero, R | 3 |
| Asmuth, DM | 1 |
| Grady, JJ | 1 |
| McKinsey, DS | 1 |
| Green, S | 1 |
| Andron, L | 1 |
| Pollard, RB | 6 |
| Lisziewicz, J | 18 |
| Foli, A | 10 |
| Wainberg, M | 1 |
| Schmidt-Wolf, IG | 1 |
| Rockstroh, JK | 1 |
| Schlegel, U | 1 |
| Pels, H | 1 |
| Mey, U | 1 |
| Strehl, J | 1 |
| Weiss, R | 1 |
| Huhn, D | 1 |
| Gwilt, PR | 1 |
| Manouilov, KK | 1 |
| McNabb, J | 1 |
| Swindells, SS | 1 |
| Lafeuillade, A | 2 |
| Poggi, C | 2 |
| Hittinger, G | 1 |
| Counillon, E | 1 |
| Emilie, D | 1 |
| Stebbing, J | 1 |
| Nelson, M | 1 |
| Orkin, C | 1 |
| Mandalia, S | 1 |
| Bower, M | 1 |
| Pozniak, A | 1 |
| Gazzard, B | 1 |
| Fumero, E | 1 |
| Blanckenberg, DH | 1 |
| Horban, A | 1 |
| Beniowski, M | 1 |
| Boron-Kaczmarska, A | 1 |
| Trocha, H | 1 |
| Halota, W | 1 |
| Schmidt, RE | 1 |
| Fatkenheuer, G | 1 |
| Jessen, H | 6 |
| Lange, JM | 2 |
| Kelly, LM | 1 |
| Malhotra, U | 1 |
| Bosch, RJ | 3 |
| Wang, R | 1 |
| Collier, A | 2 |
| McElrath, MJ | 1 |
| López, M | 2 |
| Benito, JM | 2 |
| Lozano, S | 2 |
| Barreiro, P | 4 |
| Martínez, P | 1 |
| González-Lahoz, J | 4 |
| Soriano, V | 4 |
| Provencher, VM | 1 |
| Coccaro, E | 1 |
| Lacasse, JJ | 1 |
| Schang, LM | 1 |
| Frank, I | 3 |
| Fiscus, S | 1 |
| Valentine, F | 1 |
| Segal, Y | 1 |
| Ruan, P | 1 |
| Gulick, R | 1 |
| Wood, K | 1 |
| Estep, S | 1 |
| Fox, L | 1 |
| Nevin, T | 1 |
| Stevens, M | 1 |
| Eron, JJ | 2 |
| Joshi, SR | 1 |
| Butala, N | 1 |
| Patwardhan, MR | 1 |
| Daver, NG | 1 |
| Kelkar, D | 1 |
| Paton, NI | 2 |
| Aboulhab, J | 2 |
| Samarasinghe, YP | 1 |
| Boffito, M | 1 |
| Di Perri, G | 2 |
| Swindells, S | 1 |
| Cohen, CJ | 2 |
| Berger, DS | 1 |
| Tashima, KT | 1 |
| Liao, Q | 1 |
| Pobiner, BF | 1 |
| Snidow, JW | 1 |
| Pakes, GE | 1 |
| Hernandez, JE | 1 |
| Whitman, L | 2 |
| Bakare, N | 2 |
| Blick, G | 1 |
| Shalit, P | 1 |
| Peterson, D | 1 |
| Tennenberg, A | 1 |
| Schrader, S | 2 |
| Rashbaum, B | 1 |
| Farthing, C | 1 |
| Herman, D | 1 |
| Norris, D | 1 |
| Greiger, P | 1 |
| Groff, A | 2 |
| Lova, L | 2 |
| Asmuth, D | 1 |
| Hermans, P | 1 |
| De Wit, S | 1 |
| Sommereijns, B | 1 |
| O'Doherty, E | 1 |
| Clumeck, N | 1 |
| Zala, C | 5 |
| Salomón, H | 2 |
| Cahn, P | 2 |
| Nunnari, G | 1 |
| Leto, D | 1 |
| Sullivan, J | 1 |
| Xu, Y | 1 |
| Mehlman, KE | 1 |
| Kulkosky, J | 1 |
| Pomerantz, RJ | 1 |
| Bloch, MT | 1 |
| Smith, DE | 1 |
| Quan, D | 1 |
| Kaldor, JM | 1 |
| Zaunders, JJ | 2 |
| Petoumenos, K | 1 |
| Irvine, K | 1 |
| Law, M | 2 |
| Grey, P | 2 |
| Finlayson, RJ | 1 |
| McFarlane, R | 1 |
| Kelleher, AD | 2 |
| Carr, A | 2 |
| Cooper, DA | 3 |
| Ballesteros, C | 1 |
| Capa, L | 1 |
| Sempere, J | 1 |
| Bakshi, RP | 1 |
| Hamzeh, F | 1 |
| Rosenkranz, SL | 1 |
| Cramer, YS | 1 |
| Ussery, M | 1 |
| Lewin, SR | 1 |
| Murray, JM | 1 |
| Solomon, A | 1 |
| Wightman, F | 1 |
| Cameron, PU | 1 |
| Purcell, DJ | 1 |
| Bloch, M | 1 |
| Smith, D | 3 |
| Voelker, R | 1 |
| Malley, SD | 1 |
| Grange, JM | 1 |
| Hamedi-Sangsari, F | 3 |
| Vila, JR | 1 |
| Pellegrino, P | 1 |
| Profizi, N | 1 |
| Thiebaut, C | 1 |
| Vila, J | 3 |
| Biron, F | 3 |
| Nugier, F | 3 |
| Vallet, T | 3 |
| Peyramond, D | 4 |
| Lucht, F | 1 |
| Fresard, A | 1 |
| Grange, J | 1 |
| Malley, S | 1 |
| Villani, P | 1 |
| Regazzi, MB | 1 |
| Giacchino, R | 1 |
| Raharinivo, B | 1 |
| Meylan, PR | 1 |
| Montaner, JS | 4 |
| Conway, B | 1 |
| Raboud, J | 1 |
| Patenaude, P | 1 |
| Rae, S | 2 |
| O'Shaughnessy, MV | 1 |
| Schechter, MT | 1 |
| Matteo, PS | 1 |
| Simonelli, C | 1 |
| Comar, M | 1 |
| Zanussi, S | 1 |
| De Paoli, P | 1 |
| Tirelli, U | 1 |
| Giacca, M | 1 |
| Barguès, G | 1 |
| Seigneurin, JM | 1 |
| De Antoni, A | 1 |
| Cohen, J | 1 |
| Nokta, M | 2 |
| Loesch, K | 1 |
| Rutschmann, OT | 4 |
| Opravil, M | 4 |
| Iten, A | 2 |
| Malinverni, R | 3 |
| Vernazza, PL | 3 |
| Bucher, HC | 2 |
| Bernasconi, E | 3 |
| Sudre, P | 1 |
| Leduc, D | 2 |
| Yerly, S | 3 |
| Perrin, LH | 2 |
| Hirschel, B | 4 |
| Minoli, L | 2 |
| Wainberg, MA | 1 |
| Gallo, RC | 1 |
| Finzi, D | 2 |
| Siliciano, RF | 2 |
| De Boer, RJ | 1 |
| Boucher, CA | 1 |
| Perelson, AS | 1 |
| Boelaert, JR | 1 |
| Sperber, K | 1 |
| Torres, RA | 2 |
| Bellman, PC | 1 |
| Barr, M | 1 |
| Luzzati, R | 1 |
| Fendt, D | 1 |
| Ramarli, D | 1 |
| Broccali, G | 1 |
| Concia, E | 1 |
| Romanelli, F | 1 |
| Pomeroy, C | 1 |
| Smith, KM | 1 |
| Nichols, J | 1 |
| Rosenbaum, M | 1 |
| Lieberman, J | 3 |
| Clerici, M | 1 |
| Tinelli, C | 4 |
| Marchal, F | 1 |
| Perrin, L | 2 |
| Grunke, M | 1 |
| Dechant, C | 1 |
| Löw, P | 1 |
| Rascu, A | 1 |
| Kalden, JR | 1 |
| Harrer, T | 1 |
| Barry, M | 1 |
| Clarke, S | 1 |
| Mulcahy, F | 1 |
| Back, D | 1 |
| Gelone, SP | 1 |
| Kostman, JR | 1 |
| Rosenberg, E | 2 |
| Seminari, E | 1 |
| Alberici, F | 1 |
| Walker, B | 2 |
| Goodrich, J | 1 |
| Khardori, N | 1 |
| Rana, KZ | 1 |
| Simmons, KA | 1 |
| Dudley, MN | 1 |
| Neyts, J | 1 |
| De Clercq, E | 1 |
| Ravot, E | 2 |
| Fidler, S | 1 |
| Weber, J | 1 |
| Gibbs, MA | 1 |
| Sorensen, SJ | 1 |
| Hellinger, JA | 1 |
| Iwane, MK | 1 |
| Smith, JJ | 1 |
| Fleishman, AN | 1 |
| Perez, G | 1 |
| Skowron, G | 1 |
| Giordano, MF | 1 |
| Accetta, G | 1 |
| Cooper, EC | 1 |
| Frost, KR | 1 |
| Mo, T | 1 |
| Raboud, JM | 1 |
| Alexander, CS | 1 |
| Rouleau, D | 2 |
| Harrigan, PR | 1 |
| de Mendoza, C | 1 |
| Moore, RD | 2 |
| Wong, WM | 1 |
| Keruly, JC | 2 |
| McArthur, JC | 1 |
| Cepeda, JA | 1 |
| Wilks, D | 1 |
| Bucher, H | 1 |
| Tambussi, G | 1 |
| Lazzarin, A | 1 |
| Johnson, D | 1 |
| Shuster, J | 1 |
| Nkoghe, D | 1 |
| Kola, L | 1 |
| Léonard, P | 1 |
| Demonty, J | 1 |
| Moutschen, M | 1 |
| Ledergerber, B | 1 |
| Telenti, A | 1 |
| Fagard, C | 1 |
| Kline, MW | 1 |
| Calles, NR | 1 |
| Simon, C | 1 |
| Schwarzwald, H | 1 |
| Ponceau, B | 1 |
| Bouhour, D | 1 |
| Boibieux, A | 1 |
| Verrier, B | 1 |
| Stranford, SA | 1 |
| Ong, JC | 1 |
| Martinez-Marino, B | 1 |
| Busch, M | 1 |
| Hecht, FM | 1 |
| Kahn, J | 1 |
| Levy, JA | 1 |
| Longhurst, HJ | 1 |
| Pinching, AJ | 1 |
| Laughon, SK | 1 |
| Shinn, LL | 1 |
| Nunley, JR | 1 |
| Sassaki, MG | 1 |
| Souza, CA | 1 |
| Siciliano, RF | 1 |
| Leite, AG | 1 |
| Padilha, SL | 1 |
| Taylor, S | 1 |
| Ferguson, NM | 1 |
| Cane, PA | 1 |
| Anderson, RM | 1 |
| Pillay, D | 1 |
| Sanne, I | 1 |
| Smego, RA | 1 |
| Mendelow, BV | 1 |
| Chaisson, RE | 1 |
| Mascolini, M | 3 |
| Santiago, LG | 2 |
| Santiago, L | 1 |
| Gilden, D | 2 |
| Falkenberg, J | 1 |
| Torres, G | 2 |
| Bowers, M | 1 |
| Zachary, KC | 1 |
| Davis, B | 1 |
| Bartnof, HS | 1 |
| Fakuda, D | 1 |
| Gallant, JE | 1 |
| Gortner, C | 1 |
| Hanna, L | 1 |
| Levin, J | 1 |
| Follansbee, S | 1 |
| Deeks, S | 1 |
| Bartnoff, H | 1 |
| Weinberg, A | 1 |
| Havlir, DV | 1 |
| Gilbert, PB | 1 |
| Bennett, K | 1 |
| Collier, AC | 1 |
| Hirsch, MS | 1 |
| Tebas, P | 1 |
| Adams, EM | 1 |
| Wheat, LJ | 1 |
| Goodwin, D | 1 |
| Schnittman, S | 1 |
| Holohan, MK | 1 |
| Richman, DD | 1 |
| Hudson, J | 1 |
| Chuah, J | 1 |
| Mallal, S | 1 |
| Hoy, J | 1 |
| Doong, N | 1 |
| French, M | 1 |
| Deeks, SG | 1 |
| Barditch-Crovo, P | 1 |
| Smith, A | 1 |
| Miller, M | 1 |
| McGowan, I | 1 |
| Coakley, DF | 1 |
| Joyner, S | 1 |
| Lee, D | 1 |
| Hay, P | 1 |
| Lau, R | 1 |
| Valencia, E | 1 |
| Díaz, B | 1 |
| Piccinini, G | 1 |
| Comolli, G | 1 |
| Reed, W | 1 |
| Vichinsky, EP | 1 |
| Ochoa, C | 1 |
| Kijak, G | 1 |
| Federico, A | 1 |
| Perez, H | 1 |
| Colebunders, R | 1 |
| Florence, E | 1 |
| Ostyn, B | 1 |
| Karim, F | 1 |
| Bendele, RA | 1 |
| Richardson, FC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Exploratory, Open-Label, Randomized Trial to Evaluate the Ability of Interleukin-2 (IL-2) to Enhance HIV-Specific Immunity and Influence the Time to Virologic Relapse Following Withdrawal of Potent Antiretroviral Therapy[NCT00038259] | 21 participants | Interventional | Completed | ||||
| A Phase I/II Dosing Study of the Safety and Antiretroviral Activity of Hydroxyurea Alone and in Combination With ddI Compared With ddI Alone in Subjects With HIV Infection[NCT00001074] | Phase 1 | 140 participants | Interventional | Completed | |||
| A Randomized Phase II Study of the Safety, Immunologic, and Virologic Effects of Cyclosporine A in Conjunction With Trizivir(R) and Kaletra(R) Versus Trizivir(R) and Kaletra(R) Alone During Primary HIV-1 Infection[NCT00084149] | Phase 2 | 54 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Phase I/II Safety, Tolerability, and Pharmacokinetic Study of High Dose Lopinavir/Ritonavir With or Without Saquinavir in HIV-Infected Pediatric Subjects Previously Treated With Protease Inhibitors[NCT00084058] | Phase 1/Phase 2 | 26 participants (Actual) | Interventional | Completed | |||
| A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy With Less Than 200 Copies/ml of HIV RNA in the Plasma[NCT00000916] | Phase 2 | 399 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Grade 1-4 adverse events related to study medication (NCT00084149)
Timeframe: Up to 48 weeks
| Intervention | participants (Number) |
|---|---|
| Cyclosporine | 1 |
| No Cyclosporine | 0 |
(NCT00084149)
Timeframe: At Week 48
| Intervention | cells/mm^3 (Median) |
|---|---|
| Cyclosporine | 301 |
| No Cyclosporine | 287 |
(NCT00084149)
Timeframe: At Week 48
| Intervention | log10(copies/mL) (Mean) |
|---|---|
| Cyclosporine | 1.70 |
| No Cyclosporine | 1.70 |
(NCT00084149)
Timeframe: At 48 weeks after the start of treatment
| Intervention | log10(copies/mL) (Median) |
|---|---|
| Cyclosporine | 1.88 |
| No Cyclosporine | 1.92 |
(NCT00084149)
Timeframe: Week 48
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyclosporine | 27 |
| No Cyclosporine | 13 |
(NCT00084149)
Timeframe: At Week 12
| Intervention | log10(copies/mL) (Median) |
|---|---|
| Cyclosporine | 2.22 |
| No Cyclosporine | 2.13 |
(NCT00084149)
Timeframe: At Week 24
| Intervention | log10(copies/mL) (Median) |
|---|---|
| Cyclosporine | 2.12 |
| No Cyclosporine | 1.96 |
22 reviews available for hydroxyurea and HIV Coinfection
| Article | Year |
|---|---|
Barriers to HIV Cure.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood-Brain Barrier; CD4-Positive T-Lymphocy | 2016 |
Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocyte | 2011 |
Oral and dental care and treatment protocols for the management of HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotic Prophylaxis; Antiretroviral Thera | 2002 |
Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.
Topics: Animals; Bone Marrow Cells; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Hum | 2003 |
Treatment options of AIDS-related lymphoma.
Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Hydroxyurea; I | 2003 |
Safety of hydroxyurea in the treatment of HIV infection.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dose-Response Relationship, Drug; Drug Syner | 2004 |
Antiviral drugs that target cellular proteins may play major roles in combating HIV resistance.
Topics: Animals; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Hu | 2004 |
Nucleoside/nucleotide reverse transcriptase inhibitor drug interactions.
Topics: Drug Interactions; HIV Infections; Humans; Hydroxyurea; Membrane Transport Proteins; Nucleosides; Nu | 2004 |
Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydroxyurea; | 1999 |
Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child; Clinical Trials as Topic; Didanosine; Dru | 1998 |
Hydroxyurea to inhibit human immunodeficiency virus-1 replication.
Topics: Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; HIV-1; Humans; Hydroxyurea; Virus Replica | 1999 |
Hydroxyurea and HIV: 5 years later--from antiviral to immune-modulating effects.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Nucleic Acid S | 1999 |
Hydroxyurea in the treatment of human immunodeficiency virus infection.
Topics: Clinical Trials as Topic; Enzyme Inhibitors; HIV Infections; Humans; Hydroxyurea; In Vitro Technique | 1999 |
New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide.
Topics: Cyclosporine; HIV Infections; Humans; Hydroxyurea; Immunosuppressive Agents; Nucleic Acid Synthesis | 1999 |
Hydroxyurea in the treatment of HIV-1.
Topics: Acquired Immunodeficiency Syndrome; HIV Infections; HIV-1; Humans; Hydroxyurea; Nucleic Acid Synthes | 2000 |
Strategies for rescue therapy.
Topics: HIV Infections; Humans; Hydroxyurea; Salvage Therapy | 1998 |
Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Controlled Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV | 2000 |
Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV Infectio | 2000 |
[Hydroxyurea and HIV infection].
Topics: Adult; Anti-HIV Agents; Child; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections | 2000 |
Didanosine once daily: potential for expanded use.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Liver; | 2000 |
Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?
Topics: Africa; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections | 2001 |
Transfusion therapy: a coming-of-age treatment for patients with sickle cell disease.
Topics: Adolescent; Adult; Aged; Anemia, Sickle Cell; Bacteremia; Blood Group Antigens; Blood Substitutes; B | 2001 |
43 trials available for hydroxyurea and HIV Coinfection
| Article | Year |
|---|---|
Anti-HIV agents. Long-term use of hydroxyurea.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyure | 2000 |
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions | 2002 |
A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administra | 2003 |
Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dr | 2003 |
Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; DNA, Viral; Drug Administration | 2003 |
A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Viral; Drug Therapy, Comb | 2004 |
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; H | 2004 |
Effect of adjunct hydroxyurea on helper T cell immunity in HIV type 1-infected patients with virological suppression.
Topics: Adult; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; HIV Infections; HIV-1; Humans; Hydr | 2004 |
Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; F | 2004 |
Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Viral; Drug Therapy, Comb | 2005 |
Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2005 |
Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Drug-Re | 2005 |
Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms.
Topics: Anti-HIV Agents; Apoptosis; Cell Proliferation; Cells, Cultured; Didanosine; Dose-Response Relations | 2005 |
Use of hydroxyurea in heavily pretreated patients with HIV infection.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Enzyme Inhibitors; Female; HIV Infect | 1999 |
Seminal reservoirs during an HIV type 1 eradication trial.
Topics: Amino Acid Sequence; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; DNA, Viral; | 2005 |
The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combinatio | 2006 |
Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients.
Topics: Anti-HIV Agents; Cytosol; Deoxyadenine Nucleotides; Didanosine; Double-Blind Method; Drug Therapy, C | 2007 |
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infection.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydrox | 2008 |
Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Comb | 1996 |
Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Evaluation Stu | 1996 |
A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; Humans; Hydroxyur | 1997 |
No therapeutic advantage from didanosine (ddI) and hydroxyurea versus ddI alone in patients with HIV infection.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; RN | 1997 |
Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.
Topics: Anti-HIV Agents; Didanosine; DNA, Complementary; Drug Resistance, Microbial; Drug Therapy, Combinati | 1997 |
A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Double-Blind Method; Drug | 1998 |
Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Hydro | 1998 |
Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
Topics: Anti-HIV Agents; CD3 Complex; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymph | 1999 |
Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8- | 1999 |
Hydroxyurea as part of a salvage regimen for heavily pretreated patients with advanced HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Huma | 1999 |
Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir.
Topics: Anti-HIV Agents; Blotting, Western; CD4 Lymphocyte Count; CD4-CD8 Ratio; CD8-Positive T-Lymphocytes; | 1999 |
A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Therapy, Combination; Fem | 2000 |
Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Human | 2000 |
Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Synergism; Drug Therapy, Combination; Follow | 1998 |
Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study.
Topics: Anti-HIV Agents; Diarrhea; Didanosine; Drug Therapy, Combination; Enzyme Inhibitors; Follow-Up Studi | 2000 |
Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Inf | 1997 |
Hydroxyurea continues to show promise.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1 | 1996 |
Hydroxyurea for HIV infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; DNA Replication; Drug T | 1998 |
Hydroxyurea in HIV therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; H | 1998 |
PMPA trials recruiting.
Topics: Adenine; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; H | 1998 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carnitine; Dideox | 2001 |
Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; HIV Infections; HIV-1; H | 2001 |
Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; HIV-1; Humans; Hydroxyurea; Incidence; Pancreatitis; Re | 2001 |
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Inf | 2002 |
84 other studies available for hydroxyurea and HIV Coinfection
| Article | Year |
|---|---|
Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase.
Topics: Anti-HIV Agents; Azacitidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Infections; H | 2016 |
Widespread Natural Occurrence of Hydroxyurea in Animals.
Topics: Anemia, Sickle Cell; Animals; Antineoplastic Agents; Crustacea; HIV Infections; Humans; Hydroxyurea; | 2015 |
Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications.
Topics: Anemia, Sickle Cell; Free Radicals; Gene Expression; HIV Infections; Humans; Hydroxyurea; Models, Th | 2011 |
The lack of therapeutic benefit of adding hydroxyurea to highly active antiretroviral therapy (HAART).
Topics: Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymphocyte Count; HIV Infections; H | 2002 |
Complications of HIV therapy.
Topics: Acidosis, Lactic; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; Diarrhea; Drug The | 2000 |
Pharmacokinetics of hydroxyurea in plasma and cerebrospinal fluid of HIV-1-infected patients.
Topics: Administration, Oral; Adult; AIDS Dementia Complex; Anti-HIV Agents; Anti-Retroviral Agents; Chromat | 2003 |
Immunosuppressive drugs as an adjuvant to HIV treatment.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Hydroxyurea; Immunos | 2004 |
Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymphocyte Count; | 2004 |
Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy.
Topics: Anti-HIV Agents; Chloroquine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivu | 2004 |
Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
Topics: Acute Disease; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enzyme | 1999 |
Italian researcher continues to focus on hydroxyurea treatment for HIV.
Topics: Antineoplastic Agents; HIV Infections; Humans; Hydroxyurea; Italy | 2005 |
Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine.
Topics: ADP-ribosyl Cyclase 1; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T | 2006 |
Cancer drug may join the AIDS arsenal.
Topics: Clinical Trials as Topic; HIV Infections; Humans; Hydroxyurea | 1995 |
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.
Topics: Antiviral Agents; Asparagine; Aspartic Acid; Cell Survival; Cells, Cultured; Didanosine; Drug Synerg | 1994 |
Hydroxyurea and HIV-1 viraemia.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; Enzyme Inhibitors; HIV In | 1995 |
1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection.
Topics: Antiviral Agents; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; | 1996 |
Potential role of dideoxyinosine and hydroxyurea combination in prophylaxis of HIV infection after accidental percutaneous exposure.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; Humans; Hydroxyurea | 1997 |
Long-term suppression of HIV-1 by hydroxyurea and didanosine.
Topics: Anti-HIV Agents; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV-1; Human | 1997 |
Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydroxyurea; | 1997 |
HIV suppressed long after treatment.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Hepatitis A; HIV; HIV Infections; Humans; Hydroxy | 1997 |
Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea.
Topics: Adult; Anti-HIV Agents; Antigens, CD; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; F | 1997 |
Therapeutic advantage of hydroxyurea and didanosine combination therapy in patients previously treated with zidovudine.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Retrosp | 1998 |
HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibito | 1998 |
Antiretroviral treatment.
Topics: Anti-HIV Agents; Chloroquine; Developing Countries; Didanosine; Drug Therapy, Combination; HIV Infec | 1998 |
Amsterdam Duration of Antiretroviral Medication (ADAM) study.
Topics: Antiviral Agents; CD4-CD8 Ratio; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydroxyur | 1998 |
Effect of didanosine, stavudine, and hydroxyurea therapy on apoptosis in CD45RA+ and CD45RO+ T lymphocyte subpopulations.
Topics: Adult; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines | 1999 |
Hydroxyurea-induced neurotoxicity in HIV disease.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Male; Nervou | 1999 |
Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Flow Cytometry; HIV Infections; HIV-1; Human | 1999 |
Hydroxyurea toxicity in human immunodeficiency virus-positive patients.
Topics: Adult; Bone Marrow; Dose-Response Relationship, Drug; Enzyme Inhibitors; Follow-Up Studies; HIV Infe | 1999 |
Hydroxyurea reduces the 50% inhibitory concentration of didanosine in HIV-infected cells.
Topics: Anti-HIV Agents; Cells, Cultured; Didanosine; Drug Synergism; HIV Infections; HIV-1; Humans; Hydroxy | 1999 |
Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs.
Topics: Animals; Antiviral Agents; Cell Division; Cell Survival; Chlorocebus aethiops; Drug Synergism; Herpe | 1999 |
Targeting HIV reservoirs and reconstituting the immune system. Second annual meeting Research Institute for Genetic and Human Therapy April 18-19, 1999 Washington, DC.
Topics: Adult; AIDS Vaccines; Animals; Anti-HIV Agents; Clinical Trials as Topic; Cohort Studies; Cytopathog | 1999 |
T-cell activation: a cellular target for antiretroviral therapy.
Topics: Anti-HIV Agents; Antiviral Agents; HIV Infections; Humans; Hydroxyurea; Lymphocyte Activation; Retro | 2000 |
Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Enzyme Inhibitors; HIV Infections; Humans; H | 2000 |
Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.
Topics: Adult; Aged; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; | 2000 |
Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Periphe | 2000 |
Effects of hydroxyurea on T cell count changes during primary HIV infection.
Topics: Anti-HIV Agents; CD4-CD8 Ratio; Cohort Studies; Drug Therapy, Combination; HIV Infections; Humans; H | 2000 |
Principles of treating HIV.
Topics: Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infect | 2000 |
Hydroxyurea and hepatitis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Drug Monitoring; Female; HIV Infections; Humans; Hydr | 2000 |
Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; Enzyme | 2000 |
Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Blood Chemical Analysis; CD4 Lymphocyte Count; Didanosine; Drug Combinations | 2000 |
Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphoc | 2001 |
Drug Points: pancreatitis associated with hydroxyurea in combination with didanosine.
Topics: Acute Disease; Adult; Anti-HIV Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Hydrox | 2001 |
Melanonychia and mucocutaneous hyperpigmentation due to hydroxyurea use in an HIV-infected patient.
Topics: Antiviral Agents; Female; HIV Infections; Humans; Hydroxyurea; Hyperpigmentation; Melanosis; Middle | 2000 |
Polycythemia vera in a patient with the human immunodeficiency virus: a case report.
Topics: Anti-HIV Agents; Antineoplastic Agents; Diagnosis, Differential; Drug Administration Schedule; Drug | 2000 |
Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Didan | 2001 |
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
Topics: Adult; Amylases; Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV-1; Humans; Hydroxyurea; In | 2001 |
A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug S | 1995 |
Update on clinical trials of combination therapies for HIV infection.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Didanosine; Drug The | 1995 |
New data intensifies interest in hydroxyurea.
Topics: Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydroxyurea; Mutation; Ribonuc | 1995 |
More information on hydroxyurea.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; HIV Infections; HIV-1; Humans; Hydroxyurea | 1996 |
Dethroning AZT.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therap | 1997 |
Standard treatments for HIV, Spring 1997.
Topics: Anti-HIV Agents; Antineoplastic Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhi | 1997 |
Combination treatment -- study results.
Topics: Anti-HIV Agents; Antineoplastic Agents; Clinical Trials as Topic; Drug Interactions; Drug Therapy, C | 1996 |
Hydroxyurea.
Topics: Alopecia; Anemia; Bone Marrow; DNA Replication; Enzyme Inhibitors; HIV Infections; Humans; Hydroxyur | 1997 |
ICAAC and Hamburg: Part 3. Fruhlingstraum, or what it takes to mend an immune system.
Topics: Adjuvants, Immunologic; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Biomarkers; CD4 Lymp | 1998 |
Drug research shows easier dosing, new combinations are making gains.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Drug Therapy; Drug Therapy, Combinatio | 1998 |
Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Car | 1998 |
How do you handle those borderline cases?
Topics: Adult; AIDS-Related Opportunistic Infections; Alcoholism; Anti-HIV Agents; CD4 Lymphocyte Count; Dec | 1998 |
Hydroxyurea for HIV?
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; DNA; Drug Resistance, Microbial; Drug Therapy, Co | 1998 |
What's new, what's next?
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Carbamates; Decision Making; Dideoxynucleosides; Drug Re | 1998 |
Hydroxyurea - new observations.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combinati | 1998 |
Double protease inhibitor combinations.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; DNA, Viral; Drug Therapy, Combinati | 1998 |
Is Hydroxyurea for real?
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Com | 1998 |
Antiretroviral news.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease | 1998 |
Antivirals update.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, C | 1998 |
Hydroxyurea.
Topics: Anti-HIV Agents; Antineoplastic Agents; Clinical Trials as Topic; Contraindications; Drug Therapy, C | 1998 |
A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropan | 1998 |
Absence makes the HAART grow fonder.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Enzyme Inhibitors; HIV Infec | 1999 |
Interrupting HAART; Hydroxyurea; five+ drug therapy - report from the RIGHT Conference.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Hum | 1999 |
Extended warning on Didanosine-related pancreatitis.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Hum | 1999 |
ddI, d4T, Hydroxyurea: new pancreatitis warning.
Topics: Anti-HIV Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; H | 1999 |
Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
Topics: Anti-HIV Agents; Antimalarials; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topi | 1999 |
It's the immune system, stupid.
Topics: Animals; Anti-HIV Agents; Drug Therapy, Combination; Enzyme Inhibitors; HIV Infections; Humans; Hydr | 1999 |
Hydroxyurea, a potential new anti-HIV agent.
Topics: Didanosine; DNA Replication; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Le | 1995 |
Hydroxyurea: what it is. New Mexico AIDS InfoNet.
Topics: Anti-HIV Agents; Antineoplastic Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections | 1998 |
Fifth Conference on Retroviruses & Opportunistic Infections. Interview by Ron Baker.
Topics: AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical | 1998 |
In vitro hydroxyurea decreases Th1 cell-mediated immunity.
Topics: Cell Division; HIV Infections; Humans; Hydroxyurea; Immunity, Cellular; Interferon-gamma; Interleuki | 2001 |
Anti-HIV therapy update.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitor | 2001 |
Hydroxyurea-induced nail pigmentation in HIV patients.
Topics: Adult; Anti-HIV Agents; Black People; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Huma | 1999 |
Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes.
Topics: Cells, Cultured; Dendritic Cells; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxyure | 2002 |
Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials as Top | 2001 |
Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enzyme Inhibito | 2002 |
Adefovir nephrotoxicity and mitochondrial DNA depletion.
Topics: Adenine; Antiviral Agents; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; DNA, Mito | 2002 |